Citadel Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Citadel Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-75,600	Closed	-$8.11M	–	15640
2023 Q1	$8.11M	Sell	75,600 -141,600	-65%	-$16.3M	﹤0.01%	3083
2022 Q4	$23.9M	Buy	217,200 +120,700	+125%	+$7.83M	0.01%	1779
2022 Q3	$5.69M	Buy	96,500 +77,400	+405%	+$3.54M	﹤0.01%	3655
2022 Q2	$539K	Buy	19,100 +8,300	+77%	+$241K	﹤0.01%	8475
2022 Q1	$408K	Buy	+10,800	New	+$427K	﹤0.01%	9859

Other funds holding RXDX

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Citadel Advisors's RXDX Position: Q2 2023 in Review

Citadel Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 47,146 shares — an estimated $5.06M sold.

Citadel Advisors first reported a position in RXDX in Q1 2021 and held it in 6 quarters. The position peaked at $18.3M in Q2 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Citadel Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 47,146 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.06M.
Citadel Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Citadel Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $18.3M in Q2 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.